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Abstract
Objective: Genetic variants in STXBP1, which encodes the conserved exocytosis 
protein Munc18-1, are associated with a variety of infantile epilepsy syndromes. We 
aimed to develop an in vivo Caenorhabditis elegans model that could be used to test 
the pathogenicity of such variants in a cost-effective manner.
Methods: The CRISPR/Cas9 method was used to introduce a null mutation into 
the unc-18 gene (the C. elegans orthologue of STXBP1), thereby creating a para-
lyzed worm strain. We subsequently rescued this strain with transgenes encoding the 
human STXBP1/Munc18-1 protein (wild-type and eight different epilepsy-associ-
ated missense variants). The resulting humanized worm strains were then analyzed 
via behavioral, electrophysiological, and biochemical approaches.
Results: Transgenic expression of wild-type human STXBP1 protein fully rescued 
locomotion in both solid and liquid media to the same level as the standard wild-type 
worm strain, Bristol N2. Six variant strains (E59K, V84D, C180Y, R292H, L341P, 
R551C) exhibited impaired locomotion, whereas two (P335L, R406H) were no dif-
ferent from worms expressing wild-type STXBP1. Electrophysiological recordings 
revealed that all eight variant strains displayed less frequent and more irregular phar-
yngeal pumping in comparison to wild-type STXBP1-expressing strains. Four strains 
(V84D, C180Y, R292H, P335L) exhibited pentylenetetrazol-induced convulsions in 
an acute assay of seizure-like activity, in contrast to worms expressing wild-type 
STXBP1. No differences were seen between wild-type and variant STXBP1 strains 
in terms of mRNA abundance. However, STXBP1 protein levels were reduced to 
20%-30% of wild-type in all variants, suggesting that the mutations result in STXBP1 
protein instability.
Significance: The approach described here is a cost-effective in vivo method for 
establishing the pathogenicity of genetic variants in STXBP1 and potentially other 
conserved neuronal proteins. Furthermore, the humanized strains we created could 
potentially be used in the future for high-throughput drug screens to identify novel 
therapeutics.
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1 |  INTRODUCTION
Approximately one-third of people with epilepsy do not re-
spond to currently available treatments.1 This is likely due, 
at least in part, to a lack of knowledge of the underlying bio-
logical abnormalities that cause epilepsy and that determine 
individual responsiveness to medication. In recent years, 
genome-wide association studies of epilepsy patients have 
begun to reveal genetic variants contributing effects to vari-
ous forms of epilepsy. This could usher in a new era where 
therapies are tailored to the molecular genetic defects that 
give rise to individual epilepsies. However, achieving this 
goal requires genetically tractable animal models to study 
how specific epilepsy-associated variants lead to functional 
impairments in vivo and to eventually translate this into 
therapies that can compensate for the genetic defect. The 
high financial costs associated with traditional rodent in 
vivo models of seizure and epilepsy have led to an increased 
awareness of the potential utility of simpler, non-mammalian 
animal models for such studies over recent years.2
In 2008, a landmark study identified de novo mutations 
in STXBP1 as the cause of Ohtahara syndrome (also known 
as early infantile epileptic encephalopathy with suppres-
sion-burst) in five patients.3 Subsequent work confirmed 
this observation for Ohtahara syndrome4,5 and extended it 
to patients with West syndrome,6 focal seizures with neona-
tal onset,7 and other early onset epileptic encephalopathies.8 
More recently, an exome sequencing study of large numbers of 
patients with two early onset epileptic encephalopathies, infan-
tile spasms and Lennox-Gastaut syndrome, reported STXBP1 
to be the second most commonly mutated gene.9 More than 
100 different STXBP1 variants have been identified to date, in-
cluding missense mutations, truncating mutations, and partial/
whole gene deletions.10 It therefore appears that many cases of 
catastrophic infantile epilepsy are due to STXBP1 mutations.
STXBP1 encodes a neuronal member of the Sec1/Munc18 
(SM) protein family11 known as Munc18-1. SM proteins are 
essential for exocytosis in yeast (Sec1),12 Caenorhabditis 
elegans (UNC-18),13 and mice (Munc18-1),14 and their 
evolutionarily conserved function involves binding to mem-
brane-fusing SNARE proteins, notably syntaxin15 (hence 
the gene name: SynTaXin Binding Protein 1). Munc18-1 
can bind to isolated syntaxin in either its "closed" or "open" 
conformation and also binds to the synaptic SNARE com-
plex comprising syntaxin/SNAP-25/VAMP.16 Evidence that 
Munc18-1 binding to syntaxin is relevant to epilepsy comes 
from the observation that knockin mice expressing a constitu-
tively "open" mutant form of syntaxin 1B that is inefficiently 
sequestered by Munc18-1 exhibit fulminant epilepsy.17 
Furthermore, recent studies have reported that mutations in 
the gene encoding syntaxin 1B cause a range of different 
epilepsy syndromes in humans.18,19 Hence, mutations in the 
intracellular machinery for synaptic vesicle exocytosis are 
emerging as a cause of epilepsy.
The number of genetic variants discovered in STXBP1 
associated with epilepsy and other neurological conditions 
is increasing rapidly due to dramatic improvements in DNA 
sequencing technologies.10 However, in silico methods for 
predicting whether individual variants are pathogenic often 
do not provide consistent conclusions for the same alter-
ation.20 For example, the STXBP1/Munc18-1 amino acid 
substitution variant E59K is predicted to be deleterious by 
Sorting Intolerant From Tolerant (SIFT) but is predicted to 
be benign by PolyPhen-2.10 Work using cell culture models 
has provided important information on the functional im-
pact of STXBP1 haploinsufficiency and of several epilep-
sy-associated missense variants in vitro.3,21‒25 Ideally, such 
studies would employ animal models to establish relevant 
functional impairments in vivo, as recently reported using 
null mutations in zebrafish (stxbp1b),26 haploinsufficiency 
in mice (stxbp1),24,27 and missense mutations in C. elegans 
(unc-18)25 gene homologues. Here, we have taken a differ-
ent approach of creating humanized C. elegans strains by 
substituting expression of the endogenous worm UNC-18 
protein with transgenic expression of human Munc18-1 pro-
tein (wild-type or variant). We report our characterization 
of humanized worms harboring eight different epilepsy-as-
sociated missense variants using a variety of functional 
analyses. Locomotion assays were chosen because they 
are simple to perform and amenable to automation and 
hence could potentially be used for future high-throughput 
drug screens. An acute pentylenetetrazol (PTZ)-induced 
K E Y W O R D S
epileptic encephalopathy, exocytosis, nematode, SNARE, synapse
Key Points
• Genetic variants in STXBP1 are often associated 
with catastrophic infantile epilepsies
• Human wild-type STXBP1 can functionally re-
place its worm orthologue, UNC-18
• Expressing epilepsy-associated human STXBP1 
variants in worms causes functional impairments, 
including susceptibility to seizure-like activity
• Humanized worms offer a cost-effective approach 
to determining the pathogenicity of epilepsy-asso-
ciated variants in conserved genes
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seizure model was included as a further behavioral assay 
with relevance to epilepsy. Electrophysiological recording 
was employed to provide precise information about effects 
on neurotransmission in the pharyngeal nervous system. 
Finally, analyses of mRNA and protein expression were 
used to determine effects of STXBP1 variants on gene ex-
pression and protein stability.
2 |  MATERIALS AND METHODS
2.1 | Materials
Plasmids used for genome modification via CRISPR/Cas9 
were from Addgene. The original pMunc18-1 plasmid28 was 
a generous gift from Dr Hitoshi Kitayama (Kyoto University, 
Japan). All other materials were from Sigma-Aldrich unless 
stated otherwise.
2.2 | Nematode culture
C. elegans were grown under standard conditions on nema-
tode growth media (NGM; 2% [wt/vol] agar, 0.3% [wt/vol] 
NaCl, 0.25% [wt/vol] peptone, 1  mmol/L CaCl2, 5  μg/mL 
cholesterol, 25  mmol/L KH2PO4, 1  mmol/L MgSO4) agar 
plates. Escherichia coli OP50 was used as a food source. The 
wild-type reference strain was Bristol N2. All strains were 
cultured and assays performed at 20°C. For drug treatment 
experiments, worms were cultured for 1 week (two-three 
generations) on OP50-seeded NGM agar plates containing 
either 5 mmol/L 4-phenylbutyrate (Pb), 200 mmol/L sorbitol 
(Sb), or 200 mmol/L trehalose (Tr), as performed previously 
by Guiberson et al.25 Young adult worms were then sub-
jected to locomotion assessment on freshly made unseeded 
NGM plates containing each chemical at the concentration 
described above.
2.3 | Construction of unc-18 null 
mutant strain
The unc-18(ulv12) allele was generated using CRISPR/
Cas9, following published procedures.29 The sgRNA se-
quence used to target unc-18 was 5′-CGTTGACACCCTAG 
CCATGCGG-3’. Wild-type N2 animals were microinjected 
with a mixture of 25 ng/µL Cas9-sgRNA plasmid, 50 ng/µL 
sur-5::green fluorescent protein (GFP), and 10 ng/µL pMA122 
(PEEL-1 negative selection marker). Transgenic progeny was 
identified based on GFP expression and subsequently heat 
shocked at 34°C for 4 hours to induce PEEL-1 expression, 
thereby killing animals carrying extrachromosomal arrays. 
Surviving worms that were nonfluorescent and paralyzed 
were selected as putative unc-18 mutants. Mutations were 
confirmed by single worm polymerase chain reaction (PCR) 
using unc-18 primers up- and downstream of the Cas9 site 
(forward primer: 5′-GGGCACAGTAAGTTAGACGG-3′; 
reverse primer: 5′-GAGAAGAGCTGATCCGAACAC-3′), 
followed by DNA sequencing (MRC PPU Centre, University 
of Dundee, Dundee, UK).
2.4 | STXBP1 rescue strain construction
The original pMunc18-1 plasmid,28 containing STXBP1 
cDNA under the control of the C. elegans unc-18 promoter 
and terminator elements, was first modified by site-directed 
mutagenesis to correct an unintended ATG-GTG mutation, 
which causes a predicted amino acid substitution, M316V. 
This new plasmid encoding sequence-verified wild-type 
STXBP1 was then used as a template for further site-directed 
mutagenesis to create the eight selected epilepsy-associated 
missense mutations in Munc18-1 (E59K, V84D, C180Y, 
R291H, P335L, L341P, R406H, and R3551C). Mutagenesis 
was performed using the Quick Change Site-Directed 
Mutagenesis Kit (Stratagene). All mutations were confirmed 
by DNA sequencing.
Primers used for mutagenesis were E59K: 5′-accgaggg c atcac 
a attgtgaaggatatcaacaagcgccgagag-3′, 5′-ctctcg gcgc tt g tt g at at c c 
ttcac aattgtgatgccctcggt-3′; V84D: 5′-atcaccc catctgagaagtctga 
ccactctc tgatcagtgatttta-3′, 5′-taaaatcactgatcagagagtggtcagacttc 
tcagatggggtgat-3′; C180Y: 5′-gcagagcagatcgcaaccctgtatgccacc 
ctgaaggagtatcca-3′, 5′-tggatactccttcagggtggcatacagggttgcgatctg 










2.5 | Transformation of C. elegans
Germline transformation of  unc-18(ulv12)  worm stains 
with DNA was performed by gonadal microinjection. unc-
18(ulv12) worms were injected with wild-type or mutated 
pMunc-18-1 plasmids at 10 ng/μL along with a coinjection 
reporter construct, pTG96 (sur-5::GFP) at 25 ng/μL, to iden-
tify transformed worms. All transgenic lines were confirmed 
by endpoint PCR using STXBP1-specific primers (forward 
primer: 5′-CAAGAGGATGAACACTGGCGAG-3′; reverse 
primer: 5′-CCATCGTGAGAGCTGGTAGGTCTG-3′) and 
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GoTaq DNA polymerase (Promega). At least three inde-
pendent lines of each rescue strain (wild-type and variant) 
were used for analysis.
2.6 | Thrashing assay
Locomotion was measured in solution and quantified as 
thrashes per minute (one thrash defined as one complete 
sinusoidal movement from maximum to minimum ampli-
tude and back again), as previously described.30 Single her-
maphrodites were removed from NGM plates and placed 
in a Petri dish containing 200 μL freshly made Dent solu-
tion (140 mmol/L NaCl, 6 mmol/L KCl, 1 mmol/L CaCl2, 
1 mmol/L MgCl2, 5 mmol/L hydroxyethylpiperazine ethane 
sulfonic acid, pH 7.4 with bovine serum albumin at 0.1 mg/
mL). Assessment of locomotion was performed 10 minutes 
following immersion in solution. Ten animals per strain were 
analyzed in each experiment, and three independent experi-
ments were performed (n = 30 worms per strain in total).
2.7 | Body bend assay
Locomotion was quantified here as number of body bends 
per minute on freshly made unseeded NGM plates. A body 
bend was defined as one complete sinusoidal movement from 
maximum to minimum amplitude and back again (through 
the middle axis of the worm). Ten animals per strain were 
analyzed in each experiment, and three independent experi-
ments were performed (n = 30 worms per strain in total).
2.8 | Seizure assay
This was performed using a recently described method.31 
Briefly, worms were exposed to 7 mg/mL PTZ in Dent so-
lution for 15  minutes and then head-bobbing convulsions 
were stringently scored over 30 seconds. Both the number 
of convulsions experienced per animal and the proportion of 
worms exhibiting seizure-like activity were measured. The 
seizure-prone unc-49(e407) strain was used as a positive con-
trol and the seizure-resistant wild-type N2 strain as a negative 
control. Ten animals per strain were analyzed in each experi-
ment, and three independent experiments were performed 
(n = 30 worms per strain in total).
2.9 | Electropharyngeal recording
Electrophysiological extracellular recording was used to analyze 
pharyngeal neural and muscular activity. Electropharyngeograms 
(EPGs) were acquired with the NemaMetrix ScreenChip 
system, which uses microfluidic chambers to position the phar-
ynx of individual worms close to recording electrodes. Young 
adult worms were collected and incubated in M9 buffer con-
taining 10 mmol/L serotonin to stimulate pharyngeal pumping. 
Through adjusting the pump pressure, one worm was loaded 
into the channel in the center of the Screenchip between the re-
cording electrodes using a dissecting microscope. Pharyngeal 
electrical activity was recorded for 3 minutes, with relevant pa-
rameters being monitored, such as mean pump frequency, pump 
amplitude, pump duration, interpump interval (IPI) duration, 
and standard deviation. EPG data were acquired and analyzed 
using NemAcquire and NemAnalysis software (NemaMetrix). 
Ten worms of each strain in total were recorded in these 
experiments.
2.10 | Real-time quantitative PCR
Total RNA was extracted from worm strains using an 
RNeasy Mini Kit (QIAGEN) according to the manu-
facturer's instructions. The total yield of RNA per 
extraction was measured by NanoDrop spectrophotom-
eter (Thermo Fisher Scientific). cDNA was synthesized 
from 2000  ng RNA using MMLV reverse transcriptase 
(Promega) with Oligo(dT)s. PCR reactions were per-
formed using iTaq Univer SYBR Green Super mix (Bio-
Rad Laboratories). STXBP1-specific primers (forward 
primer: 5′-CCCTATGAGTCCCAGGTGTATT-3′; reverse 
primer: 5′-GCGTTCCAGTATCGGATTCTTC-3′) were 
used for target gene amplification, and the housekeeping 
gene cdc-42 was used for normalization, in keeping with 
published recommendations32 (cdc-42 forward primer: 
5′-GGTGGCGAGCCATACACATTAGG-3′; reverse 
primer: 5′-CTCTCCAACATCCGTTGACACTGG-3′). 
The PCR reactions were run using a CFX Connect QPCR 
System (Bio-Rad Laboratories) under the following cy-
cling conditions: an initial denaturation step of 95°C for 
3 minutes followed by 40 cycles of 10 seconds denatura-
tion (95°C), 30 seconds annealing at 58°C, and 20 seconds 
elongation at 72°C. The relative amount or fold change of 
the target gene expression was normalized relative to the 
level of cdc-42 and relative to a control sample (STXBP1 
wild-type rescue strain).
For quantitative PCR (qPCR) readings, three separate bi-
ological replicate cDNA samples were used, and each was 
measured in triplicate.
2.11 | Western blotting
Worm strains were harvested from two 60-mm-diameter NGM 
plates in chilled M9 buffer and allowed to settle on ice for 
10 minutes. After two washes in M9 buffer, the worm pellets 
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were resuspended in Tris-Glycine SDS Sample Buffer (Life 
Technologies). Protein concentrations were determined using 
a NanoDrop spectrophotometer (Thermo Fisher Scientific).
Samples of 50  µg total protein were separated by so-
dium dodecyl sulfate–polyacrylamide gel electrophoresis 
using precast 4%-12% NuPAGE Bis-Tris gels (Invitrogen) 
and then transferred to nitrocellulose membrane (PALL Life 
Sciences). The membrane was blocked overnight at 4°C in 
blocking solution (Tris-buffered saline [TBS]:  20  mmol/L 
Tris (pH 7.4), 150 mM NaCl, with 0.1% Tween 20 [TBS with 
Tween (TBST)] and 5% [wt/vol] dried skimmed milk), and 
incubated at 4°C overnight with a primary antibody in TBST 
containing 1% bovine serum albumin. After three washes 
with TBST, the blots were incubated for 1 hour at room tem-
perature with horseradish peroxidase–conjugated mouse or 
rabbit IgG secondary antibody (1:2000, Sigma-Aldrich) and 
then washed three times with TBST. Detection was performed 
using Clarity Western ECL Substrate (Bio-Rad Laboratories) 
according to the manufacturer's instructions and imaged in a 
Bio-Rad ChemiDoc XRS using ImageLab software. The pri-
mary antibodies used were rabbit anti-Munc18-1 (STXBP1; 
Abcam, 1:1000), mouse anti-GFP (Roche, 1:1000), and 
mouse anti–β-actin (Sigma-Aldrich, 1:2000). The relative 
protein expression levels were quantified by densitometry 
using ImageJ Gel Analysis software. Western blots from at 
least three independent biological replicate experiments for 
each worm strain were used for quantification.
2.12 | Statistical analysis
Data are expressed as mean  ±  standard error of the mean. 
Phenotypic differences were determined using IBM SPSS 
Statistics 24. One-way analysis of variance (ANOVA) with 
post hoc tests employing Tukey correction for multiple com-
parisons was used whenever normality and homoscedastic-
ity criteria were met. Otherwise, nonparametric tests were 
performed by the Kruskal-Wallis test with post hoc tests 
employing Dunnett correction for multiple comparisons. An 
error probability level of P  <  .05 was accepted as statisti-
cally significant and indicated with an asterisk throughout the 
study. Exact P values for each comparison are listed in the 
figure and table legends.
3 |  RESULTS
3.1 | Creation of humanized C. elegans 
strains
To assess the functional effects of epilepsy-associated 
STXBP1 variants in a living animal, we adopted a knockout/
rescue approach. First, we created a null mutant allele of the 
C. elegans STXBP1 orthologue, unc-18, using the CRISPR/
Cas9 method.29 The unc-18(ulv12) allele we generated con-
tains a 7-bp deletion that introduces a premature stop codon, 
which would truncate the predicted UNC-18 protein after only 
58 residues (Figure S1). This removes the domains of UNC-
18 that mediate binding to syntaxin (Figure 1A), an interac-
tion that is essential for neurotransmission in C. elegans.30,33 
Hence, even if the truncated mutant protein was expressed, it 
would be expected to be nonfunctional. Phenotypically, unc-
18(ulv12) worms were slow growing and virtually paralyzed 
(Video S1), similar to previously reported unc-18 null mu-
tants such as the e81 reference allele.13 We then set out to res-
cue the paralysis of these unc-18 mutant worms by expressing 
wild-type or mutant human STXBP1/Munc18-1 protein. The 
plasmid construct used contains mammalian cDNA flanked 
by the endogenous C.  elegans unc-18 promoter and termi-
nator elements,34 to ensure expression of Munc18-1 protein 
in physiologically relevant worm cell types. Eight different 
epilepsy-associated missense variants were chosen to reflect 
a range of different locations within the Munc18-1 protein 
(Figure 1A). The reported incidence of these variants ranged 
from a single patient to the most highly recurrent (seven pa-
tients for R406H; Table 1). All are evolutionarily conserved 
in the worm UNC-18 protein, suggesting an important func-
tion of each mutated amino acid (Figure S2). Mutations 
were introduced into STXBP1 by site-directed mutagenesis 
and microinjected into the gonads of unc-18(ulv12) worms. 
F I G U R E  1  Human STXBP1 (Munc18-1) protein structure 
and mutations. Crystal structure of STXBP1 (Munc18-1) bound to 
syntaxin-1 (Protein Data Bank code: 3C98) is shown, rendered using 
UCSF chimera. The positions of the 8 amino acids mutated in this 
study are highlighted as red spheres
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Endpoint PCR confirmed that all strains had successfully in-
corporated STXBP1 transgenes as extrachromosomal arrays 
(Figure S3), enabling analysis of the humanized knockout/
rescue strains.
3.2 | Functional consequences of STXBP1/
Munc18-1 variants
Upon initial inspection of the humanized strains, it was ob-
vious that wild-type Munc18-1 expression rescued the pa-
ralysis of the unc-18(ulv12) strain (Video S2). These worms 
moved in a fully coordinated manner similar to that of the 
wild-type N2 strain (Video S3). To quantify locomotion in 
the various worm strains, we measured the number of body 
bends produced over time as worms crawl over the surface 
of an agar plate.
Wild-type Bristol N2 animals moved rapidly (around 30 
body bends per minute), whereas unc-18(ulv12) worms re-
mained immobile for most of the assay period (Figure 2A). 
Transgenic expression of wild-type Munc18-1 protein re-
stored locomotion in unc-18(ulv12) worms to levels that were 
not significantly different from wild-type N2 worms (Figure 
2A), consistent with the initial visual inspection. Having con-
firmed that mammalian Munc18-1 can functionally replace 
the natural C. elegans UNC-18 protein,28 we then analyzed 
the effects of the eight epilepsy-associated variants. Six of 
the transgenic strains (E59K, V84D, C180Y, R292H, L341P, 
R551C) exhibited significantly reduced body bends on agar 
compared to control worms expressing wild-type Munc18-
1. The extent of this locomotion impairment ranged con-
siderably between variants, however; for example, R551C 
retained 92% of wild-type control Munc18-1 locomotion 
activity, whereas V84D displayed only 37% activity (Figure 
2A, Video S4). Two variants (P335L, R406H) were not sig-
nificantly different from wild-type control Munc18-1 worms. 
We then used an alternative liquid-based locomotion assay, 
to determine whether results might differ from those using 
solid media. When placed in liquid, C.  elegans swim with 
T A B L E  1  Properties of STXBP1 variants analyzed in this study
Variant Incidence Conditions References
E59K 1 NSE + ID 49
V84D 1 OS 3
C180Y 1 OS 3
R292H 5 EOEE; NSE + ID; WS 9,10,50
P335L 1 EOEE 9
L341P 1 EOEE 10
R406H 7 OS; EOEE; WS + RS 4,9,51,52
R551C 4 EOEE 10,53,54
Note: Information on the number of patients affected and diagnosed conditions 
was taken from the ClinVar database and from Stamberger et al.10
Abbreviations: EOEE, early onset epileptic encephalopathy; ID, intellectual 
disability; NSE, nonsyndromic epilepsy; OS, Ohtahara syndrome; RS, Rett 
syndrome; WS, West syndrome.
F I G U R E  2  Behavioral analyses of STXBP1 transgenic worms. 
Locomotion was quantified either by counting the number of body 
bends executed per minute as worms crawled on an agar surface (A), 
or by counting the number of thrashes per minute as worms swam in 
solution (B). Six STXBP1 variants (E59K, V84D, C180Y, R292H, 
L341P, and R551C) showed significantly defective locomotion 
compared to worms expressing wild-type STXBP1. The standard N2 
wild-type strain was included as a positive control and the paralyzed 
unc-18 null mutant strain as a negative control. Ten animals per strain 
were analyzed in each experiment, and three independent experiments 
were performed (n = 30 worms per strain in total). Data are shown as 
mean ± standard error of the mean. Statistical analysis was performed 
using one-way analysis of variance with Tukey correction for multiple 
comparisons; *P < .05. Significant P values of STXBP1 mutants are 
as follows: A, E59K (.000041), V84D (.000044), C180Y (.000178), 
R292H (.000031), L341P (.000040), and R551C (.025338); B, E59K 
(.000094), V84D (.000022), C180Y (.007994), R292H (0.000605), 
L341P (.049196), and R551C (.004297)
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a characteristic thrashing motion, enabling locomotion to be 
quantified by measuring the number of thrashes over time. 
The results in liquid media were generally similar to that seen 
on solid media; expression of wild-type Munc18-1 protein 
restored locomotion in unc-18(ulv12) worms to N2 levels and 
the same 6 variants exhibited significantly reduced locomo-
tion compared to control, albeit that the extent of inhibition in 
the variants was generally less marked in liquid (Figure 2B).
We next used an electrophysiological approach to de-
termine the effect of Munc18-1 variants on neuromuscular 
transmission in the worm pharynx. Although pharyngeal 
muscle contraction has intrinsic myogenic capacity, the 
rhythmic high-frequency contractions seen during feeding 
and in response to serotonin application require synaptic 
transmission via the pharyngeal nervous system.35,36 Typical 
examples of EPGs from extracellular recordings of pharyn-
geal electrical activity are illustrated in Figure 3A. Wild-type 
Bristol N2 worms exhibited consistently rhythmic pharyn-
geal pumping at a frequency of around 4 Hz in response to 
serotonin. In contrast, unc-18(ulv12) worms displayed irreg-
ular and infrequent pharyngeal activity, as expected due to 
the severely reduced synaptic exocytosis caused by loss of 
UNC-18 function. Expression of wild-type Munc18-1 pro-
tein rescued pharyngeal pumping frequency to levels that 
were not significantly different from N2 worms (Figure 3B), 
although pumping regularity was not quite restored to N2 lev-
els, as indicated by the slightly higher IPI standard deviation 
value (Figure 3C). All eight variants resulted in a reduced 
pumping frequency, with the V84D allele again having the 
strongest effect (Figure 3B). In theory, a reduction in the 
F I G U R E  3  Electropharyngeographic 
(EPG) recordings from STXBP1 transgenic 
worms. A, Representative EPG recordings 
from N2 wild-type (WT), Munc18 rescue, 
unc-18 null, and three of the human 
STXBP1 variants, showing overall EPG 
recording information such as waveform, 
mean pump frequency, pump duration, and 
amplitude. B, All STXBP1 variants showed 
a significantly lower overall mean pump 
frequency compared to worms expressing 
WT STXBP1. C, The interpump interval 
(IPI) duration standard deviation (SD) 
represents the regularity of the pharyngeal 
pumping rhythm. All STXBP1 variants 
had a significant increase in IPI duration 
SD, indicating that pumping in the mutant 
strains is more arrhythmic than worms 
expressing WT STXBP1. Ten animals 
per strain were analyzed, and data are 
shown as mean ± standard error of the 
mean. Statistical analysis was performed 
using one-way analysis of variance with 
Tukey correction for multiple comparisons 
(*P < .05; significant P values are shown in 
Figure S4)
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overall rate of pharyngeal contractions could be produced ei-
ther by less frequent yet still rhythmic pumping, or by more 
arrhythmic pumping. It appears that the latter is the case for 
the variants, as can be seen in the typical traces in Figure 3A, 
where periods of rhythmic, regular contractions similar to 
those seen with wild-type control are interspersed with bouts 
of inactivity. Analysis of the IPI standard deviation values 
demonstrates that there is a greatly increased variability of 
pharyngeal pumping in all the STXBP1 variants (Figure 3C), 
with some also exhibiting significant changes in pump dura-
tion or IPI duration (Figure S4).
To investigate whether the humanized strains displayed 
seizure-like activity, we took advantage of a recently devel-
oped assay.31,37 This involves incubating worms with the pro-
convulsant PTZ and measuring the number of head-bobbing 
convulsions produced. This type of PTZ-induced convulsion 
has been well characterized using γ-aminobutyric acider-
gic (GABAergic) mutants,31,38 and so we included the unc-
49(e407) strain harboring a null mutation in a worm GABAA 
receptor as a positive control. PTZ treatment induced rapid 
head bobbing in >80% of unc-49 worms tested (Video S5), 
but had no convulsant effect on wild-type N2 worms, con-
sistent with published findings (Figure 4).31,37,38 Humanized 
worms rescued with wild-type Munc18-1 behaved similarly 
to N2 worms, in that repetitive head bobbing was never ob-
served (Figure 4, Video S6). However, 10%-30% of the an-
imals expressing STXBP1 variants exhibited seizure-like 
activity in response to PTZ. Quantification of the number of 
head bobs revealed that four of the variants (V84D, C180Y, 
R292H, P335L) exhibited significantly increased convul-
sions (Figure 4). Interestingly, the P335L variant strain had 
the strongest effect in this assay (Figure 4, Video S7), even 
though it was phenotypically wild type in simple locomotion 
assays (Figure 2).
Guiberson et al25 have recently reported that treatment 
with chemical chaperones can rescue the phenotype of trans-
genic C. elegans expressing UNC-18 protein with mutations 
analogous to several STXBP1 variants. To determine whether 
we could replicate this finding using our humanized worm 
strains, we used the identical approach of culturing worms in 
the presence of 5 mmol/L phenylbutyrate (Pb), 200 mmol/L 
sorbitol (Sb), or 200 mmol/L trehalose (Tr). We chose five 
strains to analyze in body bend assays (wild-type Munc18-
1, V84D, C180Y, R292H, P335L), as these ranged from the 
most severe (V84D) to no effect (P335L) and as locomotion is 
more suitable for high-throughput drug screening than elec-
trophysiological and seizure assays. The reduced locomotion 
of C180Y was increased by both Pb and Sb, whereas R292H 
locomotion was increased by Sb only (Supplementary Figure 
S5). No effect was observed in transgenic worms expressing 
wild-type Munc18-1 or P335L, which exhibit no locomotion 
defect, indicating that the observed stimulation by Pb and Sb 
was not due to a general increase in body bends. The most 
severe mutant, V84D, was also unaffected by any of the three 
compounds, suggesting that chemical chaperones have thera-
peutic potential for some, but not all, STXBP1 variants.
3.3 | Effect of STXBP1/Munc18-1 variants 
on mRNA and protein expression
One potential explanation for the varied functional effects 
seen with different STXBP1 variants is that this simply re-
flects variability in transgene copy number or transgene 
expression. To test this, we assayed mRNA levels in the 
various strains by quantitative reverse transcription PCR 
(Figure 5A). As expected, STXBP1 mRNA was undetect-
able in the untransformed unc-18(ulv12) strain. However, 
there were no significant differences in STXBP1 mRNA 
levels between the wild-type and variant humanized 
strains, thus ruling out this trivial explanation. As it has 
been reported by several groups that posttranslational sta-
bility of Munc18-1 is reduced by epilepsy-associated mis-
sense mutations,3,21,24,25 we performed Western blotting on 
worm extracts from the humanized strains. It was evident 
F I G U R E  4  Seizure-like activity in STXBP1 transgenic worms. 
Worms were exposed to 7 mg/mL pentylenetetrazol (PTZ) in Dent 
solution for 15 minutes, and then the number of head-bobbing 
convulsions was scored over a 30-second period. The seizure-prone 
unc-49 mutant strain was used as a positive control, whereas the 
wild-type N2 was used as a negative control, as it does not undergo 
convulsions in response to PTZ exposure. Four of the variants (V84D, 
C180Y, R292H, and P335L) displayed significantly higher average 
convulsions per animal than worms expressing wild-type STXBP1. 
Ten animals per strain were analyzed in each experiment, and three 
independent experiments were performed (n = 30 worms per strain 
in total). Data are shown as mean ± standard error of the mean 
(convulsion rates were compared via the Kruskal-Wallis test with 
Dunnett multiple comparison correction; *P < .05). Significant P 
values of STXBP1 mutants are as follows: V84D (.000454), C180Y 
(.019696), R292H (.025307), and P335L (.010462)
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that all eight variants reduced the level of Munc18-1 pro-
tein compared to the wild-type control strain (Figure 5B). 
Quantification of protein abundance revealed a profound 
decrease to 20%-30% of wild-type Munc18-1 protein lev-
els (Figure 5C). Notably, there were no significant differ-
ences in Munc18-1 protein expression levels between the 
different variants, suggesting that the observed phenotypic 
differences between the humanized strains cannot be ex-
plained entirely by altered protein abundance.
4 |  DISCUSSION
In this work, we have shown using quantitative behavioral 
and electrophysiological analyses that the function of the 
C. elegans UNC-18 protein can be fully complemented by 
transgenic expression of human STXBP1/Munc18-1 protein. 
This confirmed and extended the original observation by 
Gengyo-Ando et al,28 enabling us to test the functional impact 
of eight epilepsy-associated variants. All eight were found 
to be deleterious, as they resulted in decreased STXBP1/
Munc18-1 protein abundance and in less frequent and more 
irregular pharyngeal muscle contraction. This therefore vali-
dates the prediction by SIFT that the E59K is deleterious, 
in contrast to the benign prediction made by PolyPhen-2.10 
However, the effects of the eight variants varied consider-
ably between different functional assays. For example, the 
P335L strain was indistinguishable from wild-type in loco-
motion assays, yet exhibited strong pharyngeal and seizure 
phenotypes. The reason for this is not clear, but we speculate 
that it may reflect differential demands on synaptic vesicle 
exocytosis, as described below.
Serotonin regulation of pharyngeal pumping requires 
high-frequency, high-fidelity synaptic transmission via the 
two MC neurons to achieve precise rhythmic muscle con-
traction at around 4 Hz,36 and so may be more sensitive 
to partial inhibition of STXBP1. In contrast, locomotion 
involves the concerted action of dozens of motor neurons, 
each making multiple en passant synaptic contacts with 
muscle arms, and so may have more intrinsic buffering 
capacity. In addition, the functional impact of STXBP1 
variants on synaptic exocytosis may differ between neu-
ronal cell types. For example, GABAergic synapses ex-
hibit a much higher level of spontaneous neurotransmitter 
release than cholinergic synapses in C. elegans, an effect 
that is blocked in unc-18 mutants.39 Furthermore, the ex-
pression level of molecular chaperone proteins is likely to 
differ between neurons, which could differentially affect 
the misfolding/aggregation of STXBP1 variants. As the 
worm seizure assay relies on reducing GABAergic activity 
F I G U R E  5  Detection of STXBP1 (Munc18-1) expression in 
transgenic worms. A, Transcription of STXBP1 in the transgenic worm 
strains was measured by quantitative polymerase chain reaction. None 
of the mutants’ mRNA level was significantly different from the 
wild-type STXBP1 control. B, Representative Western blots showing 
that STXBP1 (Munc18-1) protein expression levels of all mutants 
are decreased compared to the wild-type control. The top row shows 
the result using a Munc18-1 antibody; the middle row is a green 
fluorescent protein (GFP) loading control, as GFP has been used as the 
transgene selection marker; and the beta-actin protein loading control 
is shown in the bottom row. C, Based on densitometric quantification 
of STXBP1 protein expression normalized to GFP, all mutants 
exhibited significantly reduced STXBP1 protein levels compared to 
the wild-type rescue control. Data are shown as mean ± standard error 
of the mean of three independent experiments. Statistical analysis was 
performed using one-way analysis of variance with Tukey correction 
for multiple comparisons; *P < .05. Significant P values of STXBP1 
mutants are as follows: E59K (.001175), V84D (.004646), C180Y 
(.003302), R292H (.000630), P335L (.005151), L341P (.005294), 
R406H (.008460), and R551C (.009779)
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using PTZ, individual STXBP1 variants may selectively af-
fect seizure phenotypes depending on the extent to which 
they affect GABAergic versus cholinergic signaling and on 
the functional impact of coexpressed chaperones. It may 
be of interest in the future to test our humanized strains 
in other C. elegans behavioral assays, including heat-in-
duced40 and electroshock41 seizure assays. Regardless of 
the precise mechanisms involved, our data clearly show 
that it is best to use a battery of functional assays, rather 
than a single readout, when testing the functional effect of 
genetic variants.
Four of the variants studied here (E59K, R292H, L341P, 
and R551C) have not previously been tested for pathogenicity 
in cell culture or animal models. However, the four remain-
ing missense variants (V84D, C180Y, P335L, and R406H) 
have been analyzed before in one or more models, enabling 
comparison with our findings using humanized worms. All 
four variants have been shown to cause protein instability, 
based on studies using recombinant proteins (C180Y),1,21 
neuronal model cell lines (V84D, C180Y),4,21,23 primary 
cultured neurons (V84D, C180Y, P335L, R406H),24,25 or 
C. elegans containing mutations in the homologous UNC-
18 residues (P334L, R405H).25 That we find the same here 
validates our humanized worm approach and suggests that 
most disease-causing mutations destabilize the STXBP1/
Munc18-1 protein. This is consistent with the view that all 
STXBP1 epilepsy-associated mutations essentially result in 
haploinsufficiency.3,4,24
Although haploinsufficiency is clearly important, work 
published over the past few years has suggested an alter-
native pathogenic mechanism by which missense STXBP1 
mutations may act.42 It has been found that some aggre-
gation-prone mutant proteins can act as a template for 
wild-type Munc18-1 to polymerize, thereby seeding coag-
gregation and hence acting in a dominant negative man-
ner.23,25 Furthermore, STXBP1 mutant proteins have been 
shown to interact with and seed coaggregation of other neu-
ronal proteins, such as α-synuclein.23 This in turn has ther-
apeutic implications, as re-establishing expression levels of 
wild-type Munc18-1 may not be able to rescue the underly-
ing defect in such cases. The templating mechanism could 
explain why some variants have stronger phenotypes than 
others in our humanized worms, despite being expressed at 
the same level, if one assumes that the mutant Munc18-1 
seeds coaggregation with endogenous C.  elegans synaptic 
proteins. Furthermore, in studies predating the identification 
of E59K as an epilepsy-associated variant, this mutation was 
shown to strongly impair SNARE complex binding in addi-
tion to causing Munc18-1 protein instability43,44 (although 
the reported functional consequence of the SNARE complex 
effect43 was contested44). Similarly, studies of a P335A mu-
tation comparable to the P335L variant has established that 
mutation at this residue confers a gain-of-function phenotype 
that enhances Munc18-1’s stimulatory effects on SNARE 
complex assembly and exocytosis.45‒48 Interestingly, the 
V84D allele, which we found to be the most deleterious in 
humanized C. elegans and could not be rescued by chemical 
chaperones, was the only missense mutation that was un-
able to rescue neuronal viability in primary neurons derived 
from stxbp1 knockout mice.24 Therefore, although haploin-
sufficiency is undoubtedly the cause of epilepsy for many 
STXBP1 mutations, the differential severity of some variants 
suggests that additional functional defects and a capacity to 
template coaggregation of wild-type Munc18-1 with other 
synaptic proteins may be relevant in some cases.
In summary, the humanized worm approach we describe 
here provides a cheap, relatively rapid method for establish-
ing the functional impact of STXBP1 missense variants in 
living animals. This has relevance not only for epilepsy, but 
also for intellectual disability without epilepsy, as both con-
ditions are associated with STXBP1 variants.10 In addition, 
the humanized worm strains could be a useful resource for 
future drug screens to identify novel therapies. Guiberson 
et al25 have recently reported that chemical chaperones can 
ameliorate the phenotypic effects of UNC-18/STXBP1 
mutations, which we have confirmed using our humanized 
strains (Figure S5). Finally, the general strategy described 
here could potentially be applied to other neurological 
disorders caused by mutations in genes with C.  elegans 
orthologues.
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